B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy
Citations Over TimeTop 10% of 2016 papers
Abstract
Targeting B7-H3 over-expressed tumor cells with anti-B7-H3 monoclonal antibodies inhibits tumor growth. Here we demonstrated the expression of B7 family homologue 3 (B7-H3) in a wide range of human tumor cells and further investigated whether B7-H3 could be served as a target for T-cell mediated immunotherapy against human cancers. The specific cytotoxic activity of activated T cell (ATC) armed with a novel anti-CD3 x anti-B7-H3 bispecific antibody (B7-H3Bi-Ab) against tumor cell was evaluated in vitro and in vivo. In contrast with unarmed ATC, an increase in cytotoxic activity of B7-H3Bi-armed ATC against tumor cells was observed at effector/target (E/T) ratios of 5:1, 10:1, and 20:1. Moreover, B7-H3Bi-armed ATC secreted more IFN-γ, TNF-α and IL-2 than unarmed ATC. Infusion of B7-H3Bi-armed ATC inhibited tumor growth in severe combined immunodeficiency (SCID) xenograft models, along with a significant survival benefit. Therefore, treatment with novel B7-H3Bi-armed ATC will be a promising strategy for current cancer immunotherapy.
Related Papers
- A Study of Motivations and the Change of Motivations of College Volunteers in Beijing Olympic Games——Taking Volunteers in Beijing Normal University as an Example(2010)
- Beijing Citizen's Living Changes in 20 Years——Analysis Based on the Time Allocation Investigation(2007)
- → Evaluating to Beijing diagnosis related groups(2011)1 cited
- → Sport Event and City Image: 2008 Beijing Olympic Games Case(2010)
- Investigation report on current operating situation of Beijing breakfast program(2004)